OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Impact of proton pump inhibitors on the onset of gastrointestinal immune‐related adverse events during immunotherapy
Angioletta Lasagna, Federica Mascaro, Simone Figini, et al.
Cancer Medicine (2023) Vol. 12, Iss. 19, pp. 19530-19536
Open Access | Times Cited: 11
Angioletta Lasagna, Federica Mascaro, Simone Figini, et al.
Cancer Medicine (2023) Vol. 12, Iss. 19, pp. 19530-19536
Open Access | Times Cited: 11
Showing 11 citing articles:
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
Silvia Casagrande, Giulia Boscato Sopetto, Giovanni Bertalot, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1440-1440
Open Access | Times Cited: 19
Silvia Casagrande, Giulia Boscato Sopetto, Giovanni Bertalot, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1440-1440
Open Access | Times Cited: 19
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1225-1225
Open Access | Times Cited: 8
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1225-1225
Open Access | Times Cited: 8
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis
Katsuhiko Nara, Satoru Taguchi, Sebastiano Buti, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008806-e008806
Open Access | Times Cited: 4
Katsuhiko Nara, Satoru Taguchi, Sebastiano Buti, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008806-e008806
Open Access | Times Cited: 4
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
Renata Pacholczak‐Madej, Artur Drobniak, Łukasz Stokłosa, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Renata Pacholczak‐Madej, Artur Drobniak, Łukasz Stokłosa, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management
Angioletta Lasagna, Paolo Sacchi
Cancers (2024) Vol. 16, Iss. 4, pp. 795-795
Open Access | Times Cited: 2
Angioletta Lasagna, Paolo Sacchi
Cancers (2024) Vol. 16, Iss. 4, pp. 795-795
Open Access | Times Cited: 2
Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs
Yihan Zhou, Shan Ding
Cancers (2023) Vol. 15, Iss. 23, pp. 5622-5622
Open Access | Times Cited: 5
Yihan Zhou, Shan Ding
Cancers (2023) Vol. 15, Iss. 23, pp. 5622-5622
Open Access | Times Cited: 5
Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies
Marthe August Marianne Verhaert, Sandrine Aspeslagh
European Journal of Cancer (2024) Vol. 209, pp. 114235-114235
Closed Access
Marthe August Marianne Verhaert, Sandrine Aspeslagh
European Journal of Cancer (2024) Vol. 209, pp. 114235-114235
Closed Access
Identification of risk factors for gastrointestinal immune–related adverse events associated with immune check point inhibitors
Ryo Morikawa, Kentaro Nitta, Shuntarô Yasuda, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Ryo Morikawa, Kentaro Nitta, Shuntarô Yasuda, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives
Alberto Savino, A. Rossi, S. Fagiuoli, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 76-76
Open Access
Alberto Savino, A. Rossi, S. Fagiuoli, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 76-76
Open Access
PPIs increase risk of GI irAEs in patients receiving immunotherapy
Reactions Weekly (2023) Vol. 1976, Iss. 1, pp. 8-8
Closed Access
Reactions Weekly (2023) Vol. 1976, Iss. 1, pp. 8-8
Closed Access
